GSK has plans to use a research seminar later this month to stake out its claim as a powerful new competitor in cancer medicines, the group's head of U.S. operations said on Monday.
Chris Viehbacher said the seminar for investors on November 30 would focus on a number of experimental drugs, including lapatanib, a dual-action breast cancer pill, and a product known as '115, for low levels of platelets in the blood.
Insider wonders if investors will encourage growth in oncology through merger.
Now, which UK Big Pharma might be a target?
Source: Reuters
1 comment:
Don't suppose you saw the ASCO results for Lapatanib???
Post a Comment